Overview

A Study To Assess Distribution Of RO7248824 In The Central Nervous System Following Single Intrathecal Doses Of [89zr] Labeled RO7248824 In Healthy Male Participants

Status:
Recruiting
Trial end date:
2022-01-05
Target enrollment:
Participant gender:
Summary
The aim of Study BP41660 is to quantify the amount and concentration of [89Zr]DFO-RO7248824 in the brain with positron emission tomography (PET) following a single sub-pharmacological dose of RO7248824 and [89Zr]DFO-RO7248824 administered via IT injection to healthy participants.
Phase:
Phase 1
Details
Lead Sponsor:
Hoffmann-La Roche